ERBB2 and breast carcinoma: In fact, Dziawer et al. reported that trastuzumab-modified 211At-labeled AuNPs, which exhibited high affinity and cytotoxicity to the HER2-overexpressing human ovarian SKOV-3 cell line [26], is a potential prospective tool for the local treatment of HER2-positive breast cancer.